Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


Home > Press > Spectrum Pharmaceuticals acquires Renazorb(TM) and Renalan(TM) from Altair Nanotechnologies

Spectrum Pharmaceuticals, Inc. has acquired all the patent rights associated with Renazorb(TM) and Renalan(TM) from Altair Nanotechnologies, Inc., a manufacturer of nanomaterials and nano-based products. Spectrum Pharmaceuticals is a biotechnology company focused on Oncology. Both the companies are based in the US.

Spectrum Pharmaceuticals acquires Renazorb(TM) and Renalan(TM) from Altair Nanotechnologies

Irvine, CA | Posted on August 10th, 2009

This agreement amends and restates an existing, limited licensing agreement between Spectrum and Altair, for Renazorb(TM) and Renalan(TM) compound. Spectrum will now have exclusive worldwide rights to Renazorb(TM), Renalan(TM), and any related compounds in any field of use.

Under terms of the agreement, Altair would receive $0.75 million in Spectrum restricted common stock. In addition to the royalty and other payments, Altair was to receive under the prior license agreement. Altair would now receive 10% of any fees Spectrum may receive from the sub-licensing of Renazorb(TM), Renalan(TM), and any related compounds.

Update on June 7, 2006:

Altair announced it would receive 0.1 million shares of Spectrum stock for a milestone payment and an additional 0.04 million shares for product development improvements, with a total approximate value of $0.55 million, following a mutually agreed upon resolution to arbitration proceedings involving the two companies. Altair and Spectrum would continue efforts to move the RenaZorb product technology to market quickly.

Announcement (January 31, 2005):

Spectrum has acquired worldwide exclusive rights to RenaZorb (two second-generation lanthanum-based phosphate binding agents) from Altair. These novel non-aluminum, non-calcium phosphate binders which utilize Altair' proprietary lanthanum nanomaterial technology have the potential to treat hyperphosphatemia, in patients with end-stage renal disease and chronic kidney disease.

Under the terms of the agreement, Spectrum acquired an exclusive worldwide license to develop and commercialize RenaZorb(TM) for all human therapeutic and diagnostic uses. In return, Spectrum would pay to Altair an upfront payment of 0.1 million shares of restricted Spectrum common stock and would make an equity investment of $0.2 million for 38,314 shares of Altair common stock. In addition, Altair would be eligible to receive payments upon achievement of a clinical development and certain regulatory and sales milestones, in addition to royalties on potential net sales.


About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), is a biopharmaceutical company that acquires, develops and commercializes a diversified portfolio of oncology and other drug candidates that meet critical health challenges for which there are few other treatment options. The Company’s pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease.

For more information, please click here

Spectrum Pharmaceuticals, Inc.
157 Technology Drive
Irvine, CA 92618
Phone: (949) 788-6700
Fax: (949) 788-6706

Copyright ©

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

Spectrum Pharmaceuticals

Related News Press

News and information

Scientists found a natural nanostructure to control the flow of light October 4th, 2015

Horizontal magnetic tunneling in a field-effect device integrated on Silicon October 3rd, 2015

Crystal clear: Thousand-fold fluorescence enhancement in an all-polymer thin film: Griffith University researchers report breakthrough due to novel and multi-layer Colloidal Photonic Crystal structure October 2nd, 2015

Industrial Nanotech, Inc. Announces New Office in Arizona to Service the Company's New Regional and National Home Builders in Arizona and Nevada October 2nd, 2015


Accelerator Corporation Completes $62.8 Million Oversubscribed Financing September 30th, 2015

Nanometrics to Participate in the Citi 2015 Global Technology Conference August 26th, 2015

Nanostart AG: First-half figures 2015 published and new supervisory board elected : Publication of first-half figures 2015 - Shareholders' meeting elected new supervisory board August 22nd, 2015

Harris & Harris Group Portfolio Company, AgBiome, Secures $34.5 Million Series B Financing Led By Bill and Melinda Gates Foundation August 20th, 2015


Sniffing out cancer with improved 'electronic nose' sensors October 2nd, 2015

Hopes of improved brain implants October 1st, 2015

New Nanomaterials Taking Research to Mexico, Possibly into Space September 29th, 2015

Cristal Therapeutics Starts Clinical Phase I Trial with Nanomedicine CriPec® Docetaxel in Patients with Solid Tumours September 29th, 2015


Scientists found a natural nanostructure to control the flow of light October 4th, 2015

Industrial Nanotech, Inc. Announces New Office in Arizona to Service the Company's New Regional and National Home Builders in Arizona and Nevada October 2nd, 2015

Production of High Temperature Ceramics with Modified Properties in Iran October 2nd, 2015

ISO Approves 2 Int'l Nanotechnology-Related Standards Proposed by Iran October 2nd, 2015

Patents/IP/Tech Transfer/Licensing

Graphene Has a Place on the Hype Cycle, Says European Flagship Director October 1st, 2015

Wearable electronic health patches may now be cheaper and easier to make September 30th, 2015

An engineered surface unsticks sticky water droplets August 31st, 2015

Developing Component Scale Composites Using Nanocarbons August 26th, 2015


Hopes of improved brain implants October 1st, 2015

A new single-molecule tool to observe enzymes at work September 28th, 2015

DNA-based nanodevices for molecular medicine: Self-assembled DNA nanostructures can be used in molecular-scale diagnostics and as smart drug-delivery vehicles. September 25th, 2015

Los Alamos explores hybrid ultrasmall gold nanocluster for enzymatic fuel cells: New technique removes barrier to development of biofuel cells with efficient performance September 25th, 2015

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

Car Brands
Buy website traffic